Baxter pulls in one stem cell licensee

Baxter International's Biotech Group finally has signed one of its rivals in stem cell separation technology to a non-exclusive license agreement covering patents for the therapeutic uses of anti-CD34 antibodies and stem cell populations.

Applied Immune Sciences Inc. (AISX) will use the antibodies in conjunction with its CELLector stem cell